Alzamend Neuro is trading at $1.33, up 5.95%, with the reason for the October 16 rise unclear.
- No verified company-specific announcement explaining the move was found; the company’s investor-relations page lists September 16 as its latest news.
- Biotech was lower and broad market indices were also down, so the supplied sector context does not explain the gain.
- No trading-volume information was provided.